Navigation Links
Johnson & Johnson Reports 2011 First-Quarter Results
Date:4/19/2011

ttp://www.investor.jnj.com/">www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov,

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
3. Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
4. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
5. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
6. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
7. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
8. EF Johnson Technologies Announces Third Quarter Results
9. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allegations of Off-Label Promotion of Topamax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- ReportsnReports.com adds Global Medical Simulation ... as well as Global Medical Simulation Market 2015-2019 ... of its library. Complete 2015 report ... across 164 pages, talking about 7 major companies ... now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html . ...
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") announcement ... Directors ("Depomed Board") set a record date to determine ... The Depomed Board will review the request ... received today and contains the information required under Depomed,s ...
(Date:8/3/2015)... Va. , Aug. 3, 2015  Dr. ... joining Orthopaedic & Spine Center today, ... to manage their chronic pain through psychological counseling ... is a Fellowship-trained, certified medical psychologist with ... medicine. His vast experience ranges from assessment and ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Orthopaedic & Spine Center Introduces New Pain Psychologist 2
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... its Board of Directors declared a quarterly cash dividend of ... of record of Quest Diagnostics common stock on April 3, ... Quest Diagnostics is the world,s leading provider of diagnostic testing, ...
... 28, 2012 HistoRx, the leader in quantitative ... technology and critical elements of digital microscopy standardization.  ... the US Patent & Trademark Office advance the ... pathology to a dominant role in the industry.  ...
Cached Medicine Technology:HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 2HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 3
(Date:8/3/2015)... ... August 03, 2015 , ... They know every second counts. And when it ... offers some of the best care in the nation. For the past two months, ... average blood clot removal time in the country. During the months of June and ...
(Date:8/3/2015)... Angeles, California (PRWEB) , ... August 03, 2015 ... ... Fifth Circuit Court of Appeals ruled in favor of the firm’s client Rebecca ... ), North Cypress Medical Center must reimburse benefits for Hamsher’s residential treatment for ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... researchers from the University of Pittsburgh School of Medicine are leading a five-year, ... drugs in sub-Saharan Africa. , A cooperative agreement awarded by the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest healthcare ... lab testing and precision medicine solutions that can help pharmacists and other healthcare ... than 8.6 million adverse drug events are reported in the U.S. Pharmacogenetic ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma ... drugs, biologics and consumer health products, today welcomed the announcement by OPKO Health ... Drug Application for a new treatment for chronic kidney disease (CKD) and vitamin ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... 3, 2011) A drug that targets a specific ... than half of the people who take it. The drug, ... the results from the largest group of patients to take ... presented at the annual meeting of the American Society of ...
... of Allergy and Infectious Diseases (NIAID), part of the National ... exposed to HIV shut down, and how they can be ... of surface proteins that the immune system can use, like ... activate the cell or to damp down its activity. However, ...
... research study investigates the challenges that pen and ... the use of electronic health records. Understanding these ... supported by health IT. Focusing on referrals ... from the specialists back to the referring physician, ...
... Journal of Traumatic Stress finds that for ... happily married, communicating frequently with one,s spouse through letters ... of posttraumatic stress disorder (PTSD) symptoms after returning home. ... soldiers who returned from military deployment within the past ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... dangerous strain of E. coli bacteria in Europe ... experts say. "Bacteria are constantly mutating and changing. They,re ... different," said Dr. Bruce Hirsch, an attending physician in infectious ...
... 10-page letter addressed to Donald Berwick, administrator of the ... The ACP strongly supports the intent of the ... potential of supporting such important care delivery goals as ... pleased that,the foundation of care under this payment model, ...
Cached Medicine News:Health News:Benefit of targeted lung cancer therapy confirmed 2Health News:Paper and computer workarounds challenge but may improve health IT 2Health News:Paper and computer workarounds challenge but may improve health IT 3Health News:Letters from home may help prevent post-traumatic stress disorder in happily married soldiers 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 3Health News:Supportive of intent of ACO proposed rule, ACP expresses concern 2Health News:Supportive of intent of ACO proposed rule, ACP expresses concern 3
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
Medicine Products: